PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Research

Principle Overview: Targeting FAK and Pyk2 in Cancer Biology

PF-562271 HCl is a highly selective, ATP-competitive, and reversible inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2). These non-receptor tyrosine kinases are pivotal in cancer cell adhesion, migration, survival, and in orchestrating the tumor microenvironment. PF-562271 HCl exhibits remarkable potency—with IC₅₀ values of 1.5 nM for FAK and 14 nM for Pyk2—offering approximately 10-fold selectivity for FAK and >100-fold selectivity over most other kinases. Its robust inhibition of FAK phosphorylation (EC₅₀ = 93 ng/mL in tumor-bearing mouse models) translates to effective suppression of tumor growth and metastasis, underpinning its value for both basic and translational cancer research.

As noted in the Moret et al. (2019) reference study, the creation of small-molecule libraries with optimal selectivity and target coverage is essential for advancing kinase-targeted therapeutics. PF-562271 HCl’s data-driven selectivity profile makes it a prototypical candidate for such focused chemical biology efforts.

Experimental Workflow: Step-by-Step Protocol Enhancements

1. Compound Preparation and Storage

• Solubility: Dissolve PF-562271 HCl at concentrations ≥26.35 mg/mL in DMSO. Use gentle warming (~37°C) to facilitate dissolution. The compound is insoluble in water and ethanol—avoid these solvents to prevent precipitation.
• Aliquoting: Prepare small, single-use aliquots to minimize freeze-thaw cycles and preserve inhibitor potency.
• Storage: Store the solid at -20°C. Long-term storage of DMSO solutions is discouraged; use freshly prepared solutions promptly to ensure maximal activity.

2. In Vitro Assays

• FAK/Pyk2 Signaling Analysis: Treat cultured cancer cells (e.g., MDA-MB-231, A549) with 1–100 nM PF-562271 HCl for 1–24 hours. Assess FAK and Pyk2 phosphorylation by Western blotting using phospho-specific antibodies.
• Cell Migration and Invasion: Employ wound healing or transwell migration assays. Pre-treat cells with PF-562271 HCl for 1 hour before initiating migration/invasion, maintaining consistent dosing throughout the assay.
• Cell Viability: Perform MTT, CCK-8, or clonogenic assays after 24–72 hours of PF-562271 HCl exposure to measure effects on proliferation and survival.

3. In Vivo Studies

• Tumor Xenograft Models: Administer PF-562271 HCl via intraperitoneal injection at 10–50 mg/kg daily, as established in preclinical protocols. Monitor tumor growth, metastasis, and survival endpoints.
• Pharmacodynamics: Collect tumor tissue at serial time points to evaluate FAK phosphorylation inhibition and downstream signaling effects using immunohistochemistry or Western blotting.

4. Combination and Mechanistic Studies

• Drug Synergy: Co-treat with chemotherapeutics or immune checkpoint inhibitors to explore combinatorial effects on tumor growth inhibition and microenvironment changes.
• Biomarker Analysis: Assess changes in EMT markers, cytokine profiles, or immune cell infiltration in response to FAK/Pyk2 pathway inhibition.

Advanced Applications & Comparative Advantages

PF-562271 HCl’s nanomolar potency and selectivity empower researchers to dissect the focal adhesion kinase signaling pathway with minimal off-target interference. Several advanced use-cases include:

• Dissecting Tumor Microenvironment Modulation: Studies such as "PF-562271 HCl: Beyond FAK/Pyk2 Inhibition in Tumor Microenvironment" highlight the compound’s ability to modulate cancer-associated macrophages and pre-metastatic niche formation, extending beyond direct cytotoxicity to influence immune and stromal cell interactions.
• Precision Inhibition in Metastatic Signaling: As explored in "PF-562271 HCl: Precision FAK/Pyk2 Inhibition for Metastatic Cancer", the inhibitor is instrumental for investigating metastatic signaling networks, including emerging biomarker and circRNA pathways.
• Immunomodulation Strategies: Recent analyses ("PF-562271 HCl: Redefining FAK/Pyk2 Inhibition for Immunomodulation") demonstrate how FAK/Pyk2 inhibition can synergize with immunotherapies by altering tumor immune evasion and facilitating immune cell infiltration.

Compared to less selective FAK/Pyk2 inhibitors, PF-562271 HCl’s robust kinase selectivity minimizes confounding off-target effects—critical for both mechanistic studies and therapeutic modeling. The compound’s reversible binding profile also allows for dynamic modulation experiments, enabling precise kinetic studies of FAK/Pyk2-dependent processes.

In the context of cheminformatics-driven library design, PF-562271 HCl exemplifies an optimal probe: high selectivity, well-characterized mechanism, and validated in multiple preclinical settings.

Troubleshooting & Optimization Tips

• Compound Precipitation: If precipitation occurs upon dilution, ensure the DMSO stock is fully dissolved and warm gently. Add DMSO stock slowly into pre-warmed culture medium with vigorous mixing.
• Batch-to-Batch Variability: Confirm compound identity and purity by LC-MS or NMR for new lots. Minor impurities can impact kinase inhibition profiles at nanomolar concentrations.
• Loss of Potency in Solution: Prepare fresh working solutions just prior to use. Even short-term storage at room temperature can reduce inhibitor activity due to hydrolysis or oxidation.
• Cell Line Sensitivity Differences: FAK/Pyk2 dependency varies among cell lines; perform initial IC₅₀ titrations for each new model system.
• Assay Interference: DMSO concentrations should be minimized (<0.1% final) to avoid solvent effects on cell health or signaling. Always include matched vehicle controls.
• In Vivo Dosing: Monitor animal weight and behavior; optimize formulation (e.g., PEG400, saline/DMSO mixtures) to enhance tolerability and bioavailability.

Future Outlook: PF-562271 HCl in Next-Generation Oncology

Emerging trends position PF-562271 HCl at the forefront of translational oncology and chemical biology:

• Integrated Signaling and Immune Modulation: As described in "Advancing Translational Oncology: Strategic Insights into FAK/Pyk2 Inhibition", targeting FAK/Pyk2 supports a paradigm shift from tumor cell-centric to microenvironment- and immunity-focused strategies.
• Library Inclusion for Phenotypic Screening: The data-driven approaches championed by Moret et al. (2019) advocate for inclusion of high-selectivity inhibitors like PF-562271 HCl in focused libraries to maximize screening efficiency and actionable hits.
• Biomarker-Driven Clinical Translation: Ongoing research into FAK/Pyk2-associated biomarkers and resistance mechanisms (see "PF-562271 HCl: Advanced FAK/Pyk2 Inhibition for Cancer Research" at MolecularBeacon) may pave the way for biomarker-guided clinical development of FAK/Pyk2 inhibitors.
• Combination Therapies: The synergy of FAK/Pyk2 inhibition with immunotherapies and targeted agents is a promising avenue for overcoming resistance and improving patient outcomes.

In summary, PF-562271 HCl delivers unparalleled potency, selectivity, and versatility for cancer research workflows focused on tumor growth inhibition, FAK phosphorylation inhibition, and tumor microenvironment modulation. Its integration into optimized experimental protocols and small-molecule libraries is poised to accelerate discoveries in FAK/Pyk2 signaling and next-generation cancer therapies.